UROV News and Press, Urovant Sciences Ltd. From 06/18/20

Urovant Sciences (Nasdaq: UROV) today reported financial results for the three months and 2019 fiscal year ended March 31, 2020. The fiscal fourth quarter of 2019 marked achievement of key milestones for Urovant Sciences, including publication of results from the international EMPOWUR P...

Urovant Sciences (NASDAQ: UROV ) has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. More news on: Urovant Sciences Ltd.,...

Urovant Sciences (Nasdaq: UROV) today announced it has entered into an exclusive three-year distribution agreement with Sunovion Pharmaceuticals Inc. (Sunovion) for services to support the commercialization of vibegron, an investigational agent for the treatment of overactive bladder. Both co...

Urovant Sciences (Nasdaq: UROV) announced today that it will report fiscal year and fourth quarter 2019 results after the close of U.S. financial markets on Thursday, June 18, 2020. Management will host a conference call to discuss Urovant’s financial results at 1:30 p.m. Pacific...

Overview Urovant Sciences (NASDAQ: UROV ) is a clinical stage biopharmaceutical company focused on the development and commercialization of its lead product candidate, vibegron, an oral, once-daily, small molecule beta-3 agonist, for the treatment of overactive bladder (OAB), OAB in men...

Walt Johnston is a proven senior pharmaceutical executive with nearly 30 years’ experience specializing in global strategy. He has extensive P&L experience in delivering significant revenue growth Mr. Johnston spent the last 12 years with Astellas Pharma, most recently as ...

We have analyzed the stock price performance for all FDA approvals between 2016 and 2019. We expected to see some appreciation going into the approval date, a spike at the approval and then some leveling off - however even we were surprised to see how pronounced and reliable this pattern is. ...

James Hindman, a veteran global and strategic senior financial executive, brings extensive experience in the pharmaceutical, biologics and medical device industries to the Urovant Board Mr. Hindman most recently served as Chief Financial Officer at Allergan until its $70.5B sale to ...

Urovant Sciences (Nasdaq: UROV) announced today that President and Chief Executive Officer James Robinson will give a presentation at 7:30 a.m. Pacific / 10:30 a.m. Eastern on Tuesday, June 2, 2020, at the Jefferies Healthcare Conference, which is being held virtually. A live, audio web...

Urovant Sciences (UROV) is a stock that just recently came onto my radar when I read Terry Chrisomalis' article here on Seeking Alpha. That led me to doing my own research and discounted cash flow analysis, and I came to much the same conclusion as Terry. Although nothing is ever a certainty...